trial

Receptor Occupancy of LB-102 Using Positron Emission Tomography (PET) in Healthy Volunteers

NCTId NCT04588129
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 16 (actual)
Sponsored by LB Pharmaceuticals Inc.
Primary completion 2021-09-17
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
16 (actual)
Study type
Interventional
Allocation
Randomized
Model
Single Group
Masking
None
Start
2021-01-05
Primary completion
2021-09-17
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
LB-102

Sponsors

LB Pharmaceuticals Inc.Lead Sponsor
Washington University School of MedicineCollaborator

Investigators

1
Dean Wong, MD,PhDPrincipal Investigator

Sites

1 total
St Louis, United States

Facts & assertions

4 sourced
Enrollment
16
Phase
PHASE1
Primary Completion Date
2021-09-17
Status
COMPLETED
relationships
The graph out of here
drug
LB-102
drug
lead_sponsor
LB Pharmaceuticals Inc.
company
collaborator
Washington University School of Medicine
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Dean Wong, MD,PhD
person